
    
      The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response
      after 2nd to 5th line of chemotherapy in patients with epithelial ovarian or fallopian tube
      or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in
      a previous line, while the response to the most recent Pt-based chemotherapy must not have
      lasted more than 12 months. In addition the response between most recent 2 lines of
      chemotherapy prior start of study medication must not have lasted more than 12 months.
    
  